Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Revenue growth
Solventum Corporation's revenue growth over the twelve months to 30 June 2026 was −0.93%, down 1.8 percentage points from fiscal 2025 (0.86%). That is below the Medical Instruments & Supplies industry median of 9.20% and below the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 0.86% | 0.16 |
| FY2024 | 0.70% | (0.12) |
| FY2023 | 0.82% | — |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 2.22% | 5.26 |
| Mar 2026 | −3.04% | 0.67 |
| Dec 2025 | −3.71% | (4.38) |
| Sep 2025 | 0.67% | (3.17) |
| 6 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RGEN Repligen Corporation compare | 16.5% |
| WST West Pharmaceutical Services, Inc. compare | 12.4% |
| ATR AptarGroup, Inc. compare | 8.93% |
| ALC Alcon compare | 8.34% |
| BAX Baxter International Inc. compare | 5.36% |
| COO The Cooper Companies, Inc. compare | 4.73% |
| ALGN Align Technology, Inc. compare | 4.41% |
| SOLV Solventum Corporation | −0.93% |
| AVTR Avantor, Inc. compare | −1.57% |
| Medical Instruments & Supplies industry median | 9.20% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement